Matches in SemOpenAlex for { <https://semopenalex.org/work/W950755514> ?p ?o ?g. }
- W950755514 endingPage "417" @default.
- W950755514 startingPage "409" @default.
- W950755514 abstract "Lipo-PGE1 is the most widely used formulation of PGE1 in clinic. However, PGE1 is easier to leak out from lipo-PGE1 and this will lead to the phlebophlogosis when intravenous injection. The stability of lipo-PGE1 in storage and in vivo is also discounted. The aim of this study is to develop a long-circulating prostaglandin E1-loaded nanoemulsion modified with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG) to improve the stability and pharmacokinetics profiles of lipo-PGE1. PEGylated PGE1 nanoemulsion was prepared using a dispersing-homogenized method. The stability of nanoemulsion in 1 month was investigated. Pharmacokinetic studies were employed to evaluate the in vivo profile of the optimized nanoemulsion. The optimized nanoemulsion PGE1-PEG2000(1%)-NE showed an oil droplet size <100 nm with a surface charge of -14 mV. Approximately, 97% of the PGE1 was encapsulated in the nanoemulsion. The particle size, zeta potential, and drug loading of PGE1-PEG2000(1%)-NE were stable in 1 month. After PGE1-PEG2000(1%)-NE was intravenously administered to rats, the area under curve (AUC) and half-life of PGE1 were, respectively, 1.47-fold and 5.98-fold higher than those of lipo-PGE1 (commercial formulation). PGE1-PEG2000(1%)-NE was an ideal formulation for prolonging the elimination time of PGE1. This novel parenteral colloidal delivery system of PGE1 has a promising potential in clinic use." @default.
- W950755514 created "2016-06-24" @default.
- W950755514 creator A5010484591 @default.
- W950755514 creator A5019685128 @default.
- W950755514 creator A5020833632 @default.
- W950755514 creator A5081908047 @default.
- W950755514 creator A5088011583 @default.
- W950755514 date "2015-07-21" @default.
- W950755514 modified "2023-10-13" @default.
- W950755514 title "Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation" @default.
- W950755514 cites W119473412 @default.
- W950755514 cites W1508626722 @default.
- W950755514 cites W1768568505 @default.
- W950755514 cites W1822602603 @default.
- W950755514 cites W1965097716 @default.
- W950755514 cites W1965881735 @default.
- W950755514 cites W1966315393 @default.
- W950755514 cites W1970239046 @default.
- W950755514 cites W1971241015 @default.
- W950755514 cites W1977144433 @default.
- W950755514 cites W1991766601 @default.
- W950755514 cites W1992950008 @default.
- W950755514 cites W1994689785 @default.
- W950755514 cites W1998136977 @default.
- W950755514 cites W2000820845 @default.
- W950755514 cites W2002283652 @default.
- W950755514 cites W2004306975 @default.
- W950755514 cites W2010308409 @default.
- W950755514 cites W2011748786 @default.
- W950755514 cites W2015312408 @default.
- W950755514 cites W2019054661 @default.
- W950755514 cites W2022532590 @default.
- W950755514 cites W2024243489 @default.
- W950755514 cites W2025226890 @default.
- W950755514 cites W2032654453 @default.
- W950755514 cites W2039201937 @default.
- W950755514 cites W2045172685 @default.
- W950755514 cites W2048508787 @default.
- W950755514 cites W2053007057 @default.
- W950755514 cites W2054068500 @default.
- W950755514 cites W2056552133 @default.
- W950755514 cites W2061296910 @default.
- W950755514 cites W2061324518 @default.
- W950755514 cites W2071636590 @default.
- W950755514 cites W2073134712 @default.
- W950755514 cites W2074070212 @default.
- W950755514 cites W2076092113 @default.
- W950755514 cites W2082196682 @default.
- W950755514 cites W2086393160 @default.
- W950755514 cites W2090990359 @default.
- W950755514 cites W2100225360 @default.
- W950755514 cites W2101241316 @default.
- W950755514 cites W2101312385 @default.
- W950755514 cites W2105836276 @default.
- W950755514 cites W2110270192 @default.
- W950755514 cites W2142997746 @default.
- W950755514 cites W2163196876 @default.
- W950755514 cites W2409931914 @default.
- W950755514 cites W2417491997 @default.
- W950755514 cites W249010743 @default.
- W950755514 cites W2747628873 @default.
- W950755514 cites W4249519419 @default.
- W950755514 cites W4300362510 @default.
- W950755514 doi "https://doi.org/10.1208/s12249-015-0366-1" @default.
- W950755514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4984874" @default.
- W950755514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26195071" @default.
- W950755514 hasPublicationYear "2015" @default.
- W950755514 type Work @default.
- W950755514 sameAs 950755514 @default.
- W950755514 citedByCount "24" @default.
- W950755514 countsByYear W9507555142018 @default.
- W950755514 countsByYear W9507555142019 @default.
- W950755514 countsByYear W9507555142020 @default.
- W950755514 countsByYear W9507555142021 @default.
- W950755514 countsByYear W9507555142022 @default.
- W950755514 crossrefType "journal-article" @default.
- W950755514 hasAuthorship W950755514A5010484591 @default.
- W950755514 hasAuthorship W950755514A5019685128 @default.
- W950755514 hasAuthorship W950755514A5020833632 @default.
- W950755514 hasAuthorship W950755514A5081908047 @default.
- W950755514 hasAuthorship W950755514A5088011583 @default.
- W950755514 hasBestOaLocation W9507555141 @default.
- W950755514 hasConcept C10138342 @default.
- W950755514 hasConcept C112705442 @default.
- W950755514 hasConcept C126322002 @default.
- W950755514 hasConcept C150903083 @default.
- W950755514 hasConcept C155672457 @default.
- W950755514 hasConcept C162324750 @default.
- W950755514 hasConcept C171250308 @default.
- W950755514 hasConcept C178790620 @default.
- W950755514 hasConcept C185592680 @default.
- W950755514 hasConcept C192562407 @default.
- W950755514 hasConcept C207001950 @default.
- W950755514 hasConcept C2776964284 @default.
- W950755514 hasConcept C2779820397 @default.
- W950755514 hasConcept C2779837120 @default.
- W950755514 hasConcept C43617362 @default.
- W950755514 hasConcept C54400483 @default.